The nation’s three largest drug distributors and a major pharmaceutical manufacturer announced Friday that a supermajority of states and localities had accepted the terms of their $26 billion offer to settle thousands of civil claims related to the deadly opioid crisis. The first checks are expected to go out in early April.
or drug distributors and the drugmaker Johnson & Johnson finalized a $26 billion agreement on Friday to bring relief to states and communities affected by the opioid epidemic, in what lawyers say is a turning point in the deadly public health crisis.
Drugmaker Johnson & Johnson and three major distributors finalized nationwide settlements over their role in the opioid addiction crisis Friday, an announcement that clears the way for $26 billion to flow to nearly every state and local government in the U.S.
A federal judge in West Virginia has indefinitely postponed a trial date in a lawsuit filed by the city of Huntington and Cabell County over the opioid crisis.
“There is no vaccine to a lifetime of opioid addiction,” said Farrell, who helped initiate the litigation from his home base in Huntington, W.Va., one of the epicenters of the crisis. “We still have an underlying opioid epidemic that has been exacerbated by the covid outbreak.”
The purpose of this phase of discovery is to allow the defendants to hear first-hand the impact on public health and the safety of our community.
Paul Farrell, Jr. is widely recognized by his peers as a pioneer and authority on the diversion claims directed against the opiate prescription drug manufacturers, distributors and dispensers.
Supply side economics is premised on the idea that “supply creates it own demand.” This certainly holds true for prescription opioids.
Our mission in the opioid litigation was to bring transparency to the volume of prescription opiates sold into our communities across the country.
Riggs v. West Virginia University Health